1233868-72-8

Basic information

• Product Name: 6-nitro-N-(3,4,5-trimethoxyphenyl)quinazolin-4-amine
• Synonyms: 6-nitro-N-(3,4,5-trimethoxyphenyl)quinazolin-4-amine
• CAS NO: 1233868-72-8
• Molecular Weight: 356.338
• Mol File: 1233868-72-8.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 6-nitro-N-(3,4,5-trimethoxyphenyl)quinazolin-4-amine(CAS DataBase Reference)
• NIST Chemistry Reference: 6-nitro-N-(3,4,5-trimethoxyphenyl)quinazolin-4-amine(1233868-72-8)
• EPA Substance Registry System: 6-nitro-N-(3,4,5-trimethoxyphenyl)quinazolin-4-amine(1233868-72-8)

Safety Data

• Hazardous Substances Data: 1233868-72-8(Hazardous Substances Data)

Upstream product

• 24313-88-0 3,4,5-Trimethoxyaniline 
• 17420-30-3 5-nitroanthranilonitrile 
• 39263-34-8 N′-(2-cyano-4-nitrophenyl)-N,N-dimethylformimidamide 

Downstream Products

• 1290545-42-4 1-(4-(bis(2-chloroethyl)amino)phenyl)-3-(4-(3,4,5-trimethoxyphenylamino)quinazolin-6-yl)urea 
• 899830-01-4 N₄-(3,4,5-trimethoxyphenyl)quinazoline-4,6-diamine 

Relevant articles and documents

Exploring MDR-TB Inhibitory Potential of 4-Aminoquinazolines as Mycobacterium tuberculosis N-Acetylglucosamine-1-Phosphate Uridyltransferase (GlmUMTB) Inhibitors

Drug resistance tuberculosis is one of the challenging tasks that dictates the desperate need for the development of new antitubercular agents which operate via novel modes of action. Here, we are reporting on 4-aminoquinazolines as M. tuberculosis N-acetylglucosamine-1-phosphate uridyltransferase (GlmUMTB) inhibitors to overcome the problem of the MDR-TB. Amongst the synthesized compounds, two of them were observed to be the effective compounds of the series (IC50=6.4 μM (H37Rv), MIC=25 μM (MDR-TB) and IC50=2.9 μM (H37Rv), MIC=6.25 μM (MDR-TB), respectively).

Design, synthesis and antitumor evaluation of phenyl N-mustard-quinazoline conjugates

A series of N-mustard-quinazoline conjugates was synthesized and subjected to antitumor studies. The N-mustard pharmacophore was attached at the C-6 of the 4-anilinoquinazolines via a urea linker. To study the structure-activity relationships of these conjugates, various substituents were introduced to the C-4 anilino moiety. The preliminary antitumor studies revealed that these agents exhibited significant antitumor activity in inhibiting various human tumor cell growths in vitro. Compounds 21b, 21g, and 21h were selected for further antitumor activity evaluation against human breast carcinoma MX-1 and prostate PC-3 xenograft in animal model. These agents showed 54-75% tumor suppression with low toxicity (5-7% body-weight changes). We also demonstrate that the newly synthesized compounds are able to induce DNA cross-linking through alkaline agarose gel shift assay and inhibited cell cycle arrest at G2/M phase.